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Abstract Multiple sclerosis (MS) is an inflammatory and
demyelinating disease of the central nervous system
(CNS). Myelin oligodendrocyte glycoprotein (MOG) and
myelin oligodendrocyte basic protein (MOBP) were both
shown to be highly encephalitogenic in animal models of
MS. In contrast, the association of MOG- and MOBP-
specific humoral or cellular immune responses and MS in
humans is far less established. In this study, we sought to
analyse MOG- and MOBP-specific T-cell responses in a
large cohort of patients with various stages of the disease.
Patients with other neurological diseases and healthy sub-
jects were enrolled to serve as control study subjects. We
determined the proliferation and the secretion of IFN-c
secretion in our cohort. We found that MOG-specific T-cell
responses were higher and more frequent as compared to
MOBP-specific ones. However, both MS patients and
control study subjects had similar myelin-specific T-cell
responses at the periphery, thus calling for more precise
studies at CNS level.
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Introduction
Aetiology of multiple sclerosis (MS) is unknown, but
dysregulated immunity plays a major role, as illustrated
by the presence of cellular infiltrates composed of CD4?
and CD8? T-cells, B cells and macrophages in MS
plaques.
The myelin oligodendrocyte protein (MOG) is well
known for its ability to generate encephalitogenic T-cell
responses and induce experimental autoimmune encepha-
lomyelitis (EAE) in mice [1]. In MS patients, MOG-specific
cellular immune response takes place in the blood [2],
and at the early stages, there is intrathecal synthesis of
MOG-specific antibodies [3]. However, whereas an
association of MOG antibodies and conversion to defi-
nite MS was shown [4], this was not confirmed by
others [5].
The myelin-associated oligodendrocyte basic protein
(MOBP), has been reported to cause EAE in susceptible
mice [6]. Contrasting with MOG, MOBP has been poorly
studied in MS patients, yet MOBP-specific T-cells are
found in MS patients [7, 8].
Here, we sought to compare MOG- and MOBP-specific
cellular immune responses in a large cohort of subjects
including patients with MS, other neurological diseases
(OND) and healthy subjects (HC).
S. Jilek  G. Pantaleo  R. A. Du Pasquier
Division of Immunology and Allergy, Department of Medicine,
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon,
1011 Lausanne, Switzerland
e-mail: samantha.jilek-terrasse@chuv.ch
G. Pantaleo
e-mail: giuseppe.pantaleo@chuv.ch
M. Schluep  R. A. Du Pasquier
Division of Neurology, Department of Clinical Neurosciences,
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon,
1011 Lausanne, Switzerland
e-mail: myriam.schluep@chuv.ch
R. A. Du Pasquier (&)
Service de Neurologie, BH10, Centre Hospitalier
Universitaire Vaudois, 1011 Lausanne, Switzerland
e-mail: renaud.du-pasquier@chuv.ch
123
Neurol Sci (2013) 34:539–543
DOI 10.1007/s10072-012-1144-4
Materials and methods
Subjects
144 subjects were enrolled: 96 patients with MS and 48
control subjects. This study was accepted by our institution
ethical commission. All subjects gave their written consent
according to review board guidelines. Diagnosis of MS was
made using the revised criteria of McDonald [9]. None of
the subjects had received corticosteroids within 3 months
before enrolment. Clinical data of the cohort are given in
Table 1.
Peripheral blood mononuclear cells (PBMC)
PBMC were isolated as previously described [10] and
either used directly or frozen.
Peptides
We used six pools of 15-mer MOG peptides and four pools
of 15-mer MOBP peptides, overlapping by 10 amino acids
(aa), and spanning the entire aa sequence of the proteins
(SynPep Corporation, Dublin, CA). Each pool contained
nine 15-mers and was used at a concentration of 10 lg/ml.
Myelin-specific proliferating T-cells
Proliferation assays on freshly isolated PBMC were per-
formed such as described previously [10]. Proliferation
responses were calculated as stimulation index (SI), as
determined by the mean ratio of antigen-stimulated counts
per minute (cpm) over background cpm. Data are presented
as cumulative SI, where results of all peptide pools were
added for a given patient [10].
Myelin-specific IFN-c-secreting T-cells
Enzyme-linked immunospot (ELISPOT) assays using fro-
zen PBMC were performed such as previously described
[10]. Responses were expressed as spot-forming cells
(SFC) per 106 PBMC. Background values corresponding to
medium-stimulated PBMC were subtracted. Data are pre-
sented as cumulative SFC/106 cells where results of all
peptide pools were added for a given patient [10].
Intracellular cytokine staining (ICS) assay
PBMC were cultured for 14 days in the presence of indi-
vidual MOG peptide pools and IL-2 and an ICS assay was
performed such as previously described [11]. Data were
acquired on a LSRII flow cytometer (Becton–Dickinson,
Franklin Lakes, NJ, USA) and analysed using FlowJo
Software (Tree Star Inc., Ashland, OR, USA). Data are
presented as cumulative percent of IFN-c secreting cells
where results of all MOG peptide pools were added for a
given patient.
Statistics
Statistical analysis was performed with GraphPad Prism
software (GraphPad Software, San Diego, CA). Tests used
included Kruskal–Wallis test for non-normally distributed
variables, non-parametric Wilcoxon ranked test and two-
sided Fisher exact test. A p \ 0.05 was considered
significant.
Table 1 Clinical data of the 144 patients enrolled
Age at blood
draw in yearsa
Delay between disease onset
and study entrance in yearsa,b
Number
of relapsesc
EDSS
score
Patients
in relapse
Treated
patients
Inflammatory MS (n = 67)
CIS (30) 39 ± 20 0.8 ± 2.4 1 ± 0 2 ± 0.5 5 1
RR-MS (37) 37 ± 11 4.8 ± 7.8 3 ± 3 2.5 ± 1 18 8
Progressive MS (n = 29)
SP-MS (14) 61 ± 14 19.3 ± 20.6 3 ± 4 6 ± 3 0 0
PP-MS (15) 54 ± 11 5.5 ± 3.2 0 ± 0 3 ± 1.5 1 0
Control subjects (n = 48)
NIND (19) 39 ± 23 0.3 ± 1.9 n/a n/a n/a n/a
OIND (9) 44 ± 29 0.2 ± 0.3 n/a n/a n/a n/a
HC (20) 33 ± 14 n/a n/a n/a n/a n/a
a Number represent the median ± inter-quartile range
b Study entrance corresponded to the diagnostic procedure including drawing of blood sample
c Patients were considered as relapsing if a relapse had started less than 4 weeks prior to the blood sample draw
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Fig. 1 MOBP- and MOG-specific cellular immune responses.
a Cumulative T-cell responses against MOBP and MOG by prolif-
eration assays, where all subject responses were plotted together (left
panel). Middle panel describes the cellular immune response of the
different groups against MOBP and right panel against MOG.
b Cumulative T-cell responses against MOBP and MOG by ELISPOT
assays (IFN-c secretion assay). Proliferation and ELISPOT data are
presented as cumulative data where results of all peptide pools were
added for a given patient. SI stimulation index, SFC spot-forming
cell, NS not significant; **p \ 0.01; ***p \ 0.001
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Fig. 2 MOG-specific CD4? and CD8? T-cells are present in all
subjects after 14 days of stimulation. a All subjects were plotted on
the same graph comparing CD4? and CD8? T-cells responses.
Cumulative percentages of IFN-c secreting T-cells for the six MOG
peptide pools are shown. b Subjects were divided into the different
study subject categories and secretion of IFN-c by MOG-specific
CD4? T-cells presented as cumulative data. c Same as above for
MOG-specific CD8? T-cells. IFN-c secretion was assessed after
14 days of stimulation by ICS. NS not significant; ***p \ 0.001
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Results
MOG- and MOBP-specific cellular immune responses
were assessed by proliferation in 122, by ELISPOT in 64,
and by ICS assays in 34 subjects.
By proliferation assays, we found that 44/122 (36 %)
subjects responded to at least one pool of MOG peptides,
whereas this rate was 17/122 (14 %) for MOBP pools
(p = 0.0001). When the MOG- or MOBP-specific T-cell
responses against the individual peptide pools were sum-
med, the cumulative MOG-specific T-cell responses were
significantly higher than the cumulative MOBP ones in the
whole cohort (p \ 0.0001; Fig. 1a). However, for both
myelin proteins, there was no difference in terms of
prevalence or magnitude of responses among the different
categories of study subjects (Fig. 1a).
Using ELISPOT assay, we found that only 11/64 study
subjects (17 %) responded to at least one pool of MOG
peptides and 5/64 (8 %) to MOBP peptides (p [ 0.1,
Fig. 1b). The magnitude of the cumulative MOG-specific
T-cell responses was significantly higher than the MOBP
ones (p = 0.0049; Fig. 1b). And for a given myelin pro-
tein, there was no difference of prevalence or magnitudes
of responses between the different categories of study
subjects (Fig. 1b).
Since MOG was significantly more immunogenic than
MOBP, we sought to determine which T-cell type was
preferentially expanded after MOG peptide stimulation.
We analysed the secretion of IFN-c in 30 MS subjects and
4 control subjects by ICS in 14-day cultures. MOG-specific
responses were present in all 34 subjects. The cumulative
MOG-specific responses were higher in CD4? T-cells than
in CD8? T-cells (p \ 0.0001), without differences
between the categories of study subjects (Fig. 2).
Discussion
We found that MOG was significantly more immunogenic
than MOBP. However, there was no difference in terms of
prevalence or magnitude of cellular immune response
against one given protein between MS patients and control
subjects. Overall, the myelin-specific T-cell responses were
rather low. As for MOG, these findings are in line with a
previous study which found no difference in the T-cell
responses against MOG, either CD4? or CD8?, in MS
patients as compared to HC [2]. MOBP was much less
studied. Authors showed that MOBP-specific CD8? T-cells
were more activated in MS patients as compared to HC [8]
and that MOBP-specific T-cell responses were positively
correlated to clinical exacerbations [7]. However, others,
like us, did not find differences in the MOBP-specific T-cell
responses between MS patients and HC [6, 12].
The fact that MOG-specific CD4? T-cell response was
not higher in CIS than other categories speaks against a
significant role of these proteins shortly after disease onset.
This observation stands in sharp contrast with EAE, where
MOG-specific CD4? T-cells are instrumental in triggering
the disease [1]. Our findings may simply illustrate the fact
that this aspect of EAE pathophysiology is not represen-
tative of MS. However, one cannot rule out that myelin-
specific T-cell responses as assessed in the peripheral blood
may have underestimate the response against similar anti-
gen in the central nervous system (CNS) [11], since it is
one of the main features of antigen-specific effector T-cells
to migrate into sites of inflammation [13].
Therefore, studies examining the presence and phenotype
of myelin-specific T-cells in the CNS are warranted to deter-
mine their putative role in the immunopathogenesis of MS.
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